RxDoctor Payments Data

Kenneth Stallman, MD

Urology · San Antonio, TXNPI 1871575100

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (54.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 86.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $3,715 and has fallen 91.2% since, to $328 in 2025.

$5,488in general payments, 2019–2025

Across 33 payments — averaging $166.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • SN Holdings, LLC$142
  • Profound Medical Corp.$141
  • Biotissue Holdings Inc.$110
  • Angiodynamics, Inc.$74
  • Novartis$62
  • plus $236 from 7 others
$1,305,090in research payments, 2019–2025

Across 174 payments — averaging $7500.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medivation LLC.$1.1M
  • Pfizer$157K
  • Bayer$14K

What the payments were for

  • Travel & lodging$1,58129%
  • Food & beverage$90617%
  • Education$3,00055%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,488 in reported general payments places this provider in the 60th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$534,335
Medicare patients
905
Services billed
10,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide173$2,450,582
XtandiEnzalutamide37$527,743
NubeqaDarolutamide24$314,700
OrgovyxRelugolix116$300,337
TrelstarTriptorelin Pamoate61$143,254
MyrbetriqMirabegron91$98,020
GemtesaVibegron62$50,799
Nilutamide12$27,005
Tamsulosin Hcl840$13,053
Solifenacin Succinate159$8,636
Tolterodine Tartrate ErTolterodine Tartrate46$4,593
Finasteride372$4,208
Abiraterone Acetate16$4,193
Alfuzosin Hcl ErAlfuzosin Hcl89$2,722
Testosterone Cypionate21$2,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$51$351,136178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 878 urology providers in Texas.

Other urology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →